Latest Insider Transactions at Heron Therapeutics, Inc. (HRTX)
This section provides a real-time view of insider transactions for Heron Therapeutics, Inc. (HRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HERON THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HERON THERAPEUTICS, INC. 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 19
2024
|
Craig A Collard Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,797
+4.75%
|
-
|
|
Jul 19
2024
|
William P Forbes EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,875
+3.76%
|
-
|
|
Jul 19
2024
|
Ira Duarte EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,875
+3.59%
|
-
|
|
Jun 16
2024
|
Ira Duarte EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+11.09%
|
-
|
|
Jun 06
2024
|
William P Forbes EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+11.59%
|
-
|
|
Apr 19
2024
|
Ira Duarte EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,122
-1.26%
|
$2,244
$2.64 P/Share
|
|
Apr 19
2024
|
Ira Duarte EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,874
+4.18%
|
-
|
|
Apr 19
2024
|
William P Forbes EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,874
+4.47%
|
-
|
|
Apr 19
2024
|
Craig A Collard Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,797
+4.99%
|
-
|
|
Apr 03
2024
|
Craig A Collard Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
62,500
+20.06%
|
-
|
|
Jan 19
2024
|
Susan Rodriguez Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,948
+16.77%
|
-
|
|
Jan 19
2024
|
Waage Christian Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,948
+17.41%
|
-
|
|
Jan 19
2024
|
Sharmila Dissanaike Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,948
+16.77%
|
-
|
|
Jan 19
2024
|
Craig A Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,948
+17.49%
|
-
|
|
Jan 19
2024
|
Adam Morgan Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,948
+21.21%
|
-
|
|
Jan 13
2024
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
756
-1.33%
|
$1,512
$2.15 P/Share
|
|
Jan 13
2024
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,841
+1.61%
|
-
|
|
Nov 17
2023
|
William P Forbes EVP, Chief Development Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+24.04%
|
$25,000
$1.09 P/Share
|
|
Nov 16
2023
|
William P Forbes EVP, Chief Development Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+48.08%
|
$0
$0.94 P/Share
|
|
Nov 16
2023
|
Ira Duarte EVP, Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
85,000
+50.0%
|
$0
$0.89 P/Share
|
|
Nov 16
2023
|
Craig A Collard Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
150,000
+44.58%
|
$0
$0.92 P/Share
|
|
Oct 13
2023
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
860
-1.54%
|
$0
$0.72 P/Share
|
|
Oct 13
2023
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,484
+2.18%
|
-
|
|
Aug 22
2023
|
Craig A Collard Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
692
-1.86%
|
$692
$1.65 P/Share
|
|
Jul 25
2023
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,743
-21.7%
|
$14,743
$1.51 P/Share
|
|
Jul 25
2023
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
42,631
+38.56%
|
-
|
|
Jul 21
2023
|
Adam Morgan Director |
BUY
Open market or private purchase
|
Indirect |
2,486,744
+26.25%
|
$2,486,744
$1.37 P/Share
|
|
Jul 13
2023
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
860
-3.29%
|
$860
$1.31 P/Share
|
|
Jul 13
2023
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,485
+4.55%
|
-
|
|
Jul 13
2023
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-5.63%
|
$2,012
$1.31 P/Share
|
|
Jul 13
2023
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+7.58%
|
-
|
|
May 22
2023
|
Craig A Collard Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
691
-1.82%
|
$691
$1.45 P/Share
|
|
Apr 13
2023
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-6.29%
|
$4,024
$2.88 P/Share
|
|
Apr 13
2023
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+8.43%
|
-
|
|
Apr 13
2023
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
1,417
-4.76%
|
$2,834
$2.88 P/Share
|
|
Apr 13
2023
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+9.02%
|
-
|
|
Apr 13
2023
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
860
-3.5%
|
$1,720
$2.88 P/Share
|
|
Apr 13
2023
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,484
+4.84%
|
-
|
|
Apr 13
2023
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-4.13%
|
$4,024
$2.88 P/Share
|
|
Apr 13
2023
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+5.67%
|
-
|
|
Feb 22
2023
|
Adam Morgan Director |
BUY
Grant, award, or other acquisition
|
Direct |
37,879
+50.0%
|
-
|
|
Jan 13
2023
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-7.75%
|
$6,036
$3.17 P/Share
|
|
Jan 13
2023
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+10.24%
|
-
|
|
Jan 13
2023
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,013
-4.39%
|
$3,039
$3.17 P/Share
|
|
Jan 13
2023
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,485
+5.14%
|
-
|
|
Jan 13
2023
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-4.49%
|
$6,036
$3.17 P/Share
|
|
Jan 13
2023
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+6.12%
|
-
|
|
Jan 13
2023
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,219
-2.85%
|
$15,657
$3.17 P/Share
|
|
Jan 13
2023
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,767
+5.11%
|
-
|
|
Jan 13
2023
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-7.14%
|
$6,036
$3.17 P/Share
|